Overcoming Cancer Recurrence: The Role of Stem Cells in Treatment Challenges

Cancer remains one of the leading causes of mortality worldwide, with projections for 2026 estimating over 2 million new cases in the United States alone and more than 9.8 million across the Asia-Pacific region. In Singapore, where cancer incidence continues to rise, innovative research from leading universities is addressing a critical hurdle: post-surgical recurrence driven by cancer stem cells (CSCs). These elusive cells, often resistant to conventional therapies like chemotherapy and radiation, can lie dormant and later trigger tumor regrowth or metastasis. Traditional treatments target bulk tumor cells but frequently miss CSCs, which exhibit stem-like properties including self-renewal and immune evasion. This gap underscores the need for advanced immunotherapies capable of eliciting broad, durable immune responses across multiple cancer types.

Singapore's higher education institutions, particularly the National University of Singapore (NUS), are at the forefront of this battle, leveraging nanotechnology to develop next-generation vaccines. Their efforts align with national initiatives like Research, Innovation and Enterprise 2025 (RIE2025) and beyond, investing billions in biomedical research to position Singapore as a global hub for precision medicine.

The NICER Nanovaccine: A Game-Changer in Multi-Cancer Immunotherapy

Researchers from NUS Yong Loo Lin School of Medicine have unveiled NICER, a pioneering nanovaccine designed specifically for postoperative cancer immunotherapy. Named Nanovesicle Integrating CSC-specific antigen display and Epigenetic nano-Regulator, NICER targets both bulk cancer cells and CSCs, marking significant progress toward a multi-cancer vaccine strategy. Published in Nature Nanotechnology in September 2025 (DOI: 10.1038/s41565-025-01952-x), the study demonstrates how NICER halts tumor growth, slashes recurrence rates, and curbs metastasis in preclinical models.

Led by Professor Shawn Chen Xiaoyuan, Nasrat Muzayyin Professor in Medicine and Technology, and first author Dr. Qing You, the team collaborated with the National Center for Nanoscience and Technology at the Chinese Academy of Sciences. Prof. Chen emphasized, “This nanovaccine approach tackles hurdles in cancer therapy – the ability of stem-like tumour cells to cause cancer relapse. NICER not only activates the immune system to attack these cells but also creates lasting memory to help prevent the cancer from returning.”

Decoding the Mechanism: How NICER Trains the Immune System Step-by-Step

NICER's ingenuity lies in its multifaceted design, combining antigen presentation with epigenetic modulation for superior immune activation. Here's the process broken down:

• Antigen Source: Nanovesicles are derived from aldehyde dehydrogenase-overexpressing (ALDH+) tumors, which are CSC markers. These vesicles naturally carry both CSC-specific antigens and tumor-associated antigens (TAAs), providing a comprehensive tumor profile.
• Dendritic Cell Targeting: A dendritic cell (DC)-targeting aptamer on the nanovesicle ensures precise delivery to antigen-presenting cells.
• Epigenetic Regulation: Encapsulated nano-regulators target YTHDF1 (YTH N6-methyladenosine RNA binding protein 1), inhibiting lysosomal protease activity in DCs. This enhances cross-presentation of antigens via major histocompatibility complex class I (MHC-I) molecules, priming cytotoxic CD8+ T cells.
• Immune Memory Formation: Activated T cells eradicate CSCs and bulk cells, generating long-term memory cells that surveil for relapse.
• Synergistic Potential: When paired with immune checkpoint inhibitors (e.g., anti-PD-1), NICER amplifies T-cell infiltration and tumor control.

This step-by-step orchestration transforms the immunosuppressive tumor microenvironment into an immunogenic one, applicable across cancers sharing CSC traits.

Preclinical Triumphs: Efficacy Across Breast Cancer, Melanoma, and Beyond

In rigorous mouse models, NICER shone against breast cancer (4T1 model), melanoma (B16F10), and CSC-enriched tumors. Post-surgical administration significantly inhibited recurrence at the resection margin – a common relapse site – and reduced lung metastasis by promoting robust anti-tumor immunity. Survival rates improved markedly, with synergistic effects from checkpoint inhibitors boosting outcomes further. Dr. Qing You noted, “In laboratory models... NICER not only halted tumour growth but also reduced recurrence and lung metastasis... enhancing tumour control and survival outcomes.”

These results position NICER as a versatile tool for solid tumors prone to CSC-driven relapse.Read the full study in Nature Nanotechnology

Photo by K8 on Unsplash

Spotlight on NUS and Singapore's Research Powerhouses

NUS Yong Loo Lin School of Medicine anchors this breakthrough, with Prof. Chen directing the Nanomedicine Translational Research Programme. Collaborations extend to A*STAR, National Cancer Centre Singapore (NCCS), Duke-NUS Medical School, and NTU, fostering interdisciplinary innovation. NCCS's ongoing neoantigen-targeting dendritic cell vaccine trial for liver cancer and colorectal metastasis complements NICER, targeting 60 patients. Singapore's ecosystem, bolstered by S$37 billion in RIE2030 funding, supports such ventures, including quantum and AI integrations in biomed.NUS's AI labs enhance research efficiency.

For aspiring researchers, opportunities abound at Singapore university jobs and higher-ed research positions.

Singapore's Leadership in Global Cancer Vaccine Landscape

While global efforts like mRNA vaccines target specific mutations (e.g., KRAS in pancreatic cancer), NICER's pan-tumor approach via CSC targeting sets it apart. Singapore's clinical trial infrastructure, backed by MOH, accelerates translation – from NCCS's EBV-specific T-cell phase III trial to NICER's preclinical promise. With cancer as APAC's top incidence driver, these advances could prevent 40% of cases through early intervention and immunotherapy.

Stakeholder views: Clinicians hail NICER's potential to reduce relapse in high-risk surgeries; patients advocate for accessible trials.

Navigating Hurdles: From Bench to Bedside

• Safety profiling for human use
• Scalability of nanovesicle production
• Patient-specific customization
• Regulatory pathways in Singapore and beyond

Challenges notwithstanding, NUS's track record – including Duke-NUS's T-cell monitoring tools – paves the way.

Future Horizons: Personalized Multi-Cancer Vaccines

Next steps include clinical trials, AI-optimized antigens, and combinations with CAR-T. Prof. Chen envisions NICER as a cornerstone for personalized post-op care, potentially extending to pancreatic and lung cancers. Singapore's vision: Lead APAC in oncology innovation by 2030.

Explore career advice for research roles or rate professors at NUS.

Photo by Angelyn Sanjorjo on Unsplash

Career Opportunities in Singapore's Biomedical Research Sector

This progress highlights vibrant prospects at NUS, Duke-NUS, and collaborators. From postdocs to faculty, postdoc positions and research jobs drive innovation. Singapore's scholarships like SINGA attract global talent, fueling multi-cancer vaccine advancements.

Check higher-ed jobs, university jobs, and Singapore opportunities on AcademicJobs.com.